澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

新冠治疗股

848.365

-0.673-0.08%

涨家数：11

跌家数：7

平家数：14

市盈率：- -

高：859.163

开：856.509

低：845.518

收：849.038

成交量：1,739.44万

成交额：2.07亿

市值：2,148.69亿

流通市值：1,702.39亿

数据加载中...

总览新闻资讯

3M公司(MMM)股票3月23日收盘上涨3.81%：投资者必看的核心信息

TradingKey中文

CSL 表示出血性疾病基因疗法全球缺货

CSL有限公司正与监管机构协作制定策略确保Hemgenix持续稳定供应

今日优惠-合并与收购

CSL Seqirus将携手长期合作伙伴Sinergium Biotech 供应差异化流感疫苗组合

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK7501/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"新冠治疗股","latestPrice":848.36536,"timestamp":1774328399941,"preClose":849.03845,"halted":0,"volume":17394382,"delay":0,"changeRate":-0.000793,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-0.673096,"latestTime":"03-24 16:00:00 AEDT","open":856.50885,"high":859.1632,"low":845.5177,"amount":207408245,"amplitude":0.016072,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1774393200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774306800000,1774328400000]],"turnoverRate":0.001211,"increases":13,"decrements":7,"flats":12,"marketCap":214868672541.5,"floatMarketCap":170238830991.08594},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":859.1632,"amplitude":0.016072,"preClose":849.03845,"low":845.5177,"latestPrice":848.36536,"volume":17394382,"delay":0,"open":856.50885,"prevYearClose":900.1661,"prevWeekClose":840.804,"prevMonthClose":875.89,"prevQuarterClose":900.166,"fiveDayClose":847.439,"twentyDayClose":850.364,"sixtyDayClose":898.118,"secType":"PLATE","market":"AU","turnoverRate":0.001211,"marketCap":214868672541.5,"floatMarketCap":170238830991.08594,"timestamp":1774328399941,"nameCN":"新冠治疗股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":11,"down":7,"flat":14},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621846180","title":"3M公司(MMM)股票3月23日收盘上涨3.81%：投资者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2621846180","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621846180?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 04:16","pubTimestamp":1774296971,"startTime":"0","endTime":"0","summary":"• 3M与贝恩资本合作，以19.5亿美元收购Madison Fire & Rescue。\n• 3M的目标是到2026年实现3%的内生性增长，到2027年营业利润率达到25%。\n• 近期的股息上调和分析师的正面评论提振了投资者信心。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/Market-Movers/261711176-market-movers-mmm-20260323","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU1093756168.USD","IE000M9KFDE8.USD","BK4585","BK4533","BK4534","LU0787776722.HKD","LU0683600562.USD","BK7040","LU1064131342.USD","LU1894683264.USD","BK4206","SG9999002224.SGD","LU1894683348.USD","MMM","BK7501","LU1093756325.SGD","MMM.AU","BK4512","BK7049","LU1988902786.USD","LU2264538146.SGD","BK4588"],"gpt_icon":0},{"id":"2620471351","title":"CSL 表示出血性疾病基因疗法全球缺货","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471351","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471351?lang=zh_cn&edition=fundamental","pubTime":"2026-03-18 00:37","pubTimestamp":1773765430,"startTime":"0","endTime":"0","summary":"路透3月17日 - 澳大利亚CSLCSL.AX公司表示，其出血性疾病基因疗法Hemgenix面临暂时性全球缺货，这将推迟该药物在已上市国家的部分患者的治疗。医生们认为，高昂的价格、物流问题和潜在的治疗进展前景阻碍了血友病基因疗法的采用。CSL表示，推迟治疗可能会影响到一些符合条件的患者，这些患者原本计划在已上市的国家接受一次性治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4051K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU0170899867.USD","IE00B19Z3B42.SGD","BK7067","IE00B19Z3581.USD","BK4588","LU0321505439.SGD","LU0985481810.HKD","LU0306807586.USD","BK4533","IE00BLSP4239.USD","BK4585","BK4550","IE00BBT3K403.USD","BK4007","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4592","BK4568","BK4534","LU1057294990.SGD","LU0868494617.USD","SG9999001176.USD","LU1066053197.SGD","IE000M9KFDE8.USD","LU0289739699.SGD","SG9999002224.SGD","BK7501","LU0456855351.SGD","BK7508","LU0225771236.USD","LU1023059063.AUD","IE0002270589.USD","CSL.AU","LU0306806265.USD","LU0225284248.USD","LU0122379950.USD","SG9999011175.SGD","LU1883839398.USD","BK7511","LU0234572021.USD","SG9999002232.USD","LU0058720904.USD","SG9999003800.SGD","SG9999001176.SGD","BK4599","LU0321505868.SGD","BK4581","LU1894683264.USD","LU1894683348.USD","SG9999013999.USD"],"gpt_icon":0},{"id":"1128210509","title":"CSL有限公司正与监管机构协作制定策略 确保Hemgenix持续稳定供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1128210509","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128210509?lang=zh_cn&edition=fundamental","pubTime":"2026-03-17 23:47","pubTimestamp":1773762439,"startTime":"0","endTime":"0","summary":"全球生物技术巨头CSL有限公司近日宣布，公司已启动与相关药品监管部门的密切沟通，共同探讨保障基因疗法Hemgenix长期稳定供应的战略方案。这一举措旨在应对潜在供应链挑战，确保这款突破性血友病B治疗药物能够持续满足全球患者的临床需求。通过建立多方协作机制，CSL将优化从原料采购到成品配送的全链条管理。此次战略合作凸显了CSL对患者用药可及性的长期承诺。CSL将通过技术创新与监管协作的双重路径，持续推动罕见病治疗领域的进步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7511","BK7067","CSL.AU"],"gpt_icon":0},{"id":"2620286284","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2620286284","media":"路透中文","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620286284?lang=zh_cn&edition=fundamental","pubTime":"2026-03-17 17:45","pubTimestamp":1773740741,"startTime":"0","endTime":"0","summary":"今日优惠-合并与收购路透3月17日 - 截至格林尼治标准时间周二9:30，报导了以下竞标、兼并、收购和处置情况：** Woolworths < WHLJ.J  > 说，它已同意收购私人控股的 in2food Holdings，收购金额未披露，这家食品和服装零售商的目标是更好地控制其优质方便食品的质量和供应。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4050SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGF.AU","BK4603","BK7112","PPM.AU","BK7160","AVXX","BK4187","BK7123","BK7501","WOW.AU","BK7511","BK1147","BK7040"],"gpt_icon":1},{"id":"1138284712","title":"CSL Seqirus将携手长期合作伙伴Sinergium Biotech 供应差异化流感疫苗组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1138284712","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138284712?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 23:02","pubTimestamp":1773154962,"startTime":"0","endTime":"0","summary":"CSL有限公司旗下业务单元CSL Seqirus宣布，将与其长期合作伙伴Sinergium Biotech合作，共同供应其差异化的流感疫苗产品组合。此次合作旨在进一步拓展相关市场的疫苗可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7501","BK7067","CSL.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}